Skip to main content
. 2016 Feb 1;11(2):e0148139. doi: 10.1371/journal.pone.0148139

Fig 2. Anti-tumoral efficacy of SWCNT/CpG-2 in the invasive K-Luc glioma model.

Fig 2

(A and B) Four and eight days (indicated by black arrows) after i.c. tumor implantation, mice received intratumoral (i.t.) injections of SWCNT/CpG-2, RSS-CpG or PBS. TMZ (2.5 mg/kg) was administered daily beginning on day 4. Kaplan–Meier analysis showed SWCNT/CpG-2+TMZ significantly extended survival relative to all other treatment groups (curves significantly different P < 0.0001 by Log-rank test, n = 5).